Ripasudil Hydrochloride Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ripasudil Hydrochloride Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
41
Registered trials
5
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ripasudil Hydrochloride Hydrate can convert its Small molecule drug profile and ROCK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ripasudil Hydrochloride Hydrate (query alias: ripasudil) |
|---|---|
| Modality / target | Small molecule drug; ROCK; ROCK inhibitors |
| Highest global status | Approved |
| Originator | Kowa Co., Ltd. |
| Active developers | Kowa Pharmaceuticals America, Inc., Kowa Research Institute, Inc., Kowa Co., Ltd. |
The MCP disease footprint includes Glaucoma, Ocular Hypertension, Fuchs' Endothelial Dystrophy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| TCTR20260305002 | Phase 4 | Pending (Not yet recruiting) | 300 | Not disclosed |
| TCTR20250107001 | Phase 3 | Pending (Not yet recruiting) | 20 | Not disclosed |
| TCTR20250606004 | Phase 2 | Pending (Not yet recruiting) | 38 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Descemet Stripping Only combined with Ripasudil for treating Fuchs dystrophy at a leading Center in Spain.
Not Applicable; n=14; evaluation: Positive. Reported fields: AE = The most common side effect of ripasudil was ocular irritation, with no severe adverse events reported.
A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Patients With Fuchs Endothelial Corneal Dystrophy
Phase 2; n=65; evaluation: not stated. Reported fields: Central Corneal Endothelial Cell Density (ECD) at Week 12(Mean) = 228.05 cells/mm2 (Standard Deviation, 297.860); Central Corneal Endothelial Cell Density (ECD) at Week 12(Mean) = 468.02 cells/mm2 (Standard Deviation, 322.361); Central Corneal Endothelial Cell Density (ECD) at Week 12(Mean) = 530.86 cells/mm2 (Standard Deviation, 312.453)
PO039 DSO Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy: Two-Year ECC Outcomes
Not Applicable; n=23; evaluation: not stated. Reported fields: Central ECC = unrecordable cells/mm²
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ripasudil Hydrochloride Hydrate addresses Glaucoma, Ocular Hypertension, Fuchs' Endothelial Dystrophy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2002-09-01 | DWTI succeeded in out-licensing its ROCK inhibitors to Kowa | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Therapy for treating type 1 diabetes using rock2 and DYRK1 inhibitors”. The milestone feed surfaced a patent-application signal described as “Ripasudil based ophthalmic treatments”. The milestone feed surfaced a patent-application signal described as “A polymorphic forms of ripasudil and ripasudil hcl”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
